Core Insights - Intelligent Bio Solutions Inc. will participate in the 21st Annual Emerging Growth Equity Conference hosted by Noble Capital Markets on December 2-3, 2025 [1] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [4] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [4] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [4] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [4] Conference Details - The conference will take place at Florida Atlantic University, Boca Raton, FL, with Intelligent Bio Solutions scheduled to present on December 3, 2025, at 11:00 a.m. Eastern Time [2] - A webcast recording of the presentation will be available on the company's investor relations website and Noble's website for 90 days post-event [2]

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. Conference DetailsDate: December 2–3, 2025Location: Florida Atlantic University, Boca Raton, FL Presentation ...

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intellige ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

Financial Results - Intelligent Bio Solutions Inc. announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025[3]. - The press release detailing the financial results was issued on November 4, 2025[3]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[2].

Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today anno ...

Core Insights - Intelligent Bio Solutions Inc. reported a 50% increase in new customer accounts during the fiscal first quarter, totaling over 480 active accounts, indicating strong customer expansion and revenue momentum [1][3][4] Company Performance - The company added 33 new customer accounts in the fiscal first quarter ended September 30, 2025, compared to the same period last year [1] - Approximately 91% of new accounts were first-time adopters of the drug screening solution, while 9% were expansions within existing customer organizations [3] - The company aims to convert current momentum into sustained revenue growth and long-term value [3] Market Trends - The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of 15%, driven by increasing regulatory focus on workplace safety and demand for non-invasive testing solutions [4] - Adoption of the Intelligent Fingerprinting Drug Screening System is broadening across various industries, reflecting its scalability and alignment with modern compliance standards [5] Sector Growth - Strongest growth in customer acquisition was noted in sectors such as maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration [2] - Government administration is a newly entered sector, highlighting the expanding applicability of the company's solutions [2]

Core Insights - Intelligent Bio Solutions Inc. has secured a significant contract with a major industrial service provider in the UK, marking a key milestone in the adoption of its rapid, non-invasive drug testing technology [1][3][5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [7] - The company employs approximately 3,000 staff in the UK and Ireland, with over 30,000 employees globally [1][2] Technology Adoption - The new customer account represents one of the most significant commercial deployments for INBS in the UK, aimed at modernizing workforce safety and compliance [3] - The transition from traditional urine collection methods to INBS's technology is expected to enhance testing efficiency, reduce downtime, and improve productivity [3][4] Market Confidence and Growth - The contract highlights growing market confidence in INBS's technology, which is increasingly being adopted by large industrial operators [5] - INBS's drug testing technology is currently utilized by over 480 accounts across 24 countries, supported by 18 distribution partners [6] Business Model and Revenue Potential - The company's business model is characterized by a "razor–razor-blade" approach, focusing on long-term recurring cartridge sales and sustained revenue growth [5] - The recent contract reflects INBS's continued momentum following multiple deployments in various sectors, including transportation, construction, and mining [5]

Core Insights - Intelligent Bio Solutions Inc. (INBS) is progressing towards FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System, specifically for opiate codeine, with an anticipated timeline for clearance in the second half of 2026 [2][3] - The company is initiating clinical studies to gather additional data to support its 510(k) submission, with studies expected to conclude in the first half of 2026 [3][4] - INBS's drug testing technology has been adopted by over 450 accounts across 24 countries, indicating a strong global presence and demand for its solutions [4] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, aiming to revolutionize portable testing through fingerprint sweat analysis [5] - The Intelligent Fingerprinting Drug Screening System screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [5] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners [5]

Core Viewpoint - Intelligent Bio Solutions Inc. is progressing through the FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System, which is a novel non-invasive testing solution [1][2][3]. FDA Clearance Process - The company submitted its 510(k) premarket notification to the FDA in December 2024, and received an Additional Information request in February 2025, which included over 70 items to address [2]. - INBS responded to the FDA's questions and submitted additional information in August 2025, but the FDA has requested further information, necessitating a resubmission of the 510(k) notification [3][4]. - The device is unique as there are no comparable sweat-based products currently on the market, requiring extensive validation to demonstrate its performance [3]. Company Strategy and Market Position - The company is consulting with specialized FDA consultants to evaluate the FDA's questions and plans to provide an investor update within ten days regarding the timeline for FDA clearance [4]. - The CEO expressed confidence in the technology and emphasized the company's commitment to bringing the solution to the U.S. market while continuing to grow its international business [5]. - INBS is developing partnerships and driving sales growth outside the U.S., targeting sectors such as construction, manufacturing, transport, and drug treatment organizations [6]. Product Overview - The Intelligent Fingerprinting Drug Screening System is designed for rapid, non-invasive drug testing through fingerprint sweat analysis, screening for drugs commonly found in workplaces [6]. - The system offers quick sample collection and results in under ten minutes, making it a valuable tool for safety-critical industries [6].